Skye Bioscience to Acquire Redx Pharma in Reverse Merger, Creating Fibrx Therapeutics
SKYE sits 96% above its 52-week low of $0.276 on light trading volume (0.2× avg).
Summary
Skye Bioscience will be acquired by Redx Pharma in a reverse merger, leaving Skye shareholders with only 5.38% of the combined company. The deal includes $103.9 million in new financing and a 1-for-8 reverse stock split.
Key Events · M&A and Partnerships · SKYE
-
Reverse Merger with Redx Pharma
Skye will acquire Redx Pharma via a UK scheme of arrangement, but Redx equityholders will own 46.17% of the combined company versus only 5.38% for Skye's legacy shareholders. Redx's management team will take over leadership roles.
-
Concurrent Financing of $67.9M
Skye entered into a Securities Purchase Agreement for $67.9 million (up to $72.9 million) with accredited investors, plus a $22 million equity line facility and a $5 million warrant with Redmile Group. Redx is also raising $36 million in Series A financing.
-
1-for-8 Reverse Stock Split
The board approved a 1-for-8 reverse stock split effective August 24, 2026, to raise the share price above $1.00 and regain Nasdaq compliance. Authorized shares will decrease from 300 million to 37.5 million.
-
Legacy CVRs for Skye Shareholders
Skye shareholders will receive contingent value rights entitling them to 90% of net proceeds from any future disposition of Skye's legacy assets, including nimacimab. There is no assurance of any payment.
Analysis · SKYE · Life Sciences
A reverse merger will leave Skye Bioscience's legacy shareholders with only 5.38% of the combined company, as Redx Pharma effectively takes control. The deal includes a $67.9 million concurrent financing, a $36 million Series A investment in Redx, and a 1-for-8 reverse stock split to regain Nasdaq compliance. Current management will resign, with Redx's team taking over. The transaction is subject to shareholder approval and is expected to close by August 2027.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19M. The 52-week trading range was $0.28 to $4.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.